See more : Jinhai International Group Holdings Limited (2225.HK) Income Statement Analysis – Financial Results
Complete financial analysis of CellaVision AB (publ) (CLVSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CellaVision AB (publ), a leading company in the Medical – Devices industry within the Healthcare sector.
- NanoCarrier Co., Ltd. (4571.T) Income Statement Analysis – Financial Results
- Ibere Pharmaceuticals (IBER-WT) Income Statement Analysis – Financial Results
- Fission 3.0 Corp. (FUU.V) Income Statement Analysis – Financial Results
- InterPrivate II Acquisition Corp. (IPVA-WT) Income Statement Analysis – Financial Results
- Storm Exploration Inc. (CWVWF) Income Statement Analysis – Financial Results
CellaVision AB (publ) (CLVSF)
About CellaVision AB (publ)
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 677.29M | 639.34M | 565.55M | 471.44M | 461.77M | 364.81M | 309.31M | 265.04M | 239.39M | 216.92M | 179.85M | 169.51M | 155.40M | 131.64M | 108.97M | 100.44M | 74.57M |
| Cost of Revenue | 214.25M | 201.02M | 173.25M | 158.40M | 125.04M | 93.95M | 86.09M | 76.10M | 65.16M | 71.81M | 67.23M | 59.46M | 53.99M | 44.08M | 32.49M | 36.94M | 29.31M |
| Gross Profit | 463.04M | 438.32M | 392.30M | 313.04M | 336.73M | 270.87M | 223.22M | 188.94M | 174.23M | 145.10M | 112.63M | 110.06M | 101.41M | 87.56M | 76.49M | 63.50M | 45.25M |
| Gross Profit Ratio | 68.37% | 68.56% | 69.37% | 66.40% | 72.92% | 74.25% | 72.17% | 71.29% | 72.78% | 66.89% | 62.62% | 64.93% | 65.26% | 66.51% | 70.19% | 63.22% | 60.69% |
| Research & Development | 83.33M | 88.55M | 64.25M | 51.25M | 56.42M | 39.25M | 26.79M | 29.24M | 27.12M | 22.77M | 20.68M | 21.44M | 21.41M | 17.34M | 12.06M | 11.90M | 11.14M |
| General & Administrative | 76.03M | 73.54M | 63.08M | 50.97M | 51.39M | 37.64M | 35.57M | 28.67M | 33.79M | 36.83M | 26.65M | 29.06M | 27.01M | 23.05M | 19.29M | 16.46M | 16.07M |
| Selling & Marketing | 136.62M | 117.96M | 102.25M | 100.55M | 102.35M | 82.36M | 69.98M | 56.86M | 47.85M | 42.69M | 39.34M | 38.86M | 35.28M | 33.64M | 30.44M | 21.75M | 15.14M |
| SG&A | 212.66M | 191.50M | 165.32M | 151.52M | 153.74M | 120.01M | 105.54M | 85.53M | 81.64M | 79.52M | 66.00M | 67.92M | 62.29M | 56.68M | 49.73M | 38.21M | 31.20M |
| Other Expenses | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -90.00K | -411.00K | -75.00K | 12.00K | -227.00K |
| Operating Expenses | 295.99M | 280.05M | 229.57M | 202.77M | 210.16M | 159.26M | 132.33M | 114.77M | 108.76M | 102.29M | 86.68M | 89.35M | 83.61M | 73.61M | 61.71M | 50.12M | 42.11M |
| Cost & Expenses | 510.24M | 481.07M | 402.82M | 361.17M | 335.20M | 253.21M | 218.42M | 190.87M | 173.92M | 174.10M | 153.91M | 148.81M | 137.60M | 117.69M | 94.20M | 87.06M | 71.42M |
| Interest Income | 898.00K | 200.00K | 60.00K | 416.00K | 128.00K | 20.00K | 334.00K | 1.00K | 4.00K | 328.00K | 594.00K | 225.00K | 1.11M | 1.00K | 15.00K | 363.00K | 260.00K |
| Interest Expense | 3.26M | 2.34M | 1.87M | 2.55M | 1.50M | 159.00K | 158.00K | 37.00K | 10.00K | 534.00K | 323.00K | 517.00K | 399.00K | 3.23M | 631.00K | 693.00K | 777.00K |
| Depreciation & Amortization | 39.76M | 40.10M | 33.44M | 24.10M | 20.16M | 1.58M | 8.45M | 8.26M | 7.57M | 12.97M | 8.99M | 7.61M | 1.11M | 0.00 | 15.00K | 363.00K | 260.00K |
| EBITDA | 207.25M | 190.87M | 193.60M | 124.60M | 150.87M | 113.83M | 98.79M | 75.48M | 73.13M | 44.25M | 27.05M | 26.68M | 25.34M | 20.09M | 14.78M | 13.75M | 3.40M |
| EBITDA Ratio | 30.60% | 29.85% | 34.23% | 31.14% | 32.67% | 32.64% | 31.99% | 31.72% | 30.55% | 26.22% | 18.90% | 15.74% | 12.17% | 10.60% | 13.57% | 13.69% | 4.56% |
| Operating Income | 167.05M | 158.27M | 162.73M | 110.27M | 126.58M | 111.61M | 90.89M | 74.17M | 65.47M | 42.81M | 25.95M | 20.70M | 17.80M | 13.95M | 14.78M | 13.38M | 3.14M |
| Operating Income Ratio | 24.66% | 24.75% | 28.77% | 23.39% | 27.41% | 30.59% | 29.39% | 27.98% | 27.35% | 19.74% | 14.43% | 12.21% | 11.45% | 10.60% | 13.56% | 13.32% | 4.21% |
| Total Other Income/Expenses | -2.83M | -9.84M | -4.44M | 1.96M | 2.64M | 490.00K | -549.00K | 1.61M | 83.00K | 556.00K | -1.26M | -2.15M | 714.00K | -3.22M | -616.00K | -330.00K | -517.00K |
| Income Before Tax | 164.22M | 148.43M | 158.30M | 112.23M | 129.22M | 112.10M | 90.34M | 75.78M | 65.55M | 43.37M | 24.69M | 18.55M | 18.51M | 10.72M | 14.16M | 13.05M | 2.63M |
| Income Before Tax Ratio | 24.25% | 23.22% | 27.99% | 23.81% | 27.98% | 30.73% | 29.21% | 28.59% | 27.38% | 19.99% | 13.73% | 10.94% | 11.91% | 8.15% | 12.99% | 13.00% | 3.52% |
| Income Tax Expense | 33.91M | 30.09M | 32.96M | 22.75M | 30.05M | 23.41M | 20.62M | 15.98M | 12.73M | 11.90M | 5.76M | 12.10M | 3.88M | -27.63M | -13.56M | -12.00M | 0.00 |
| Net Income | 130.31M | 118.34M | 125.34M | 89.48M | 99.17M | 88.69M | 69.72M | 59.80M | 52.82M | 31.47M | 18.93M | 6.45M | 14.63M | 38.35M | 27.72M | 25.05M | 2.63M |
| Net Income Ratio | 19.24% | 18.51% | 22.16% | 18.98% | 21.48% | 24.31% | 22.54% | 22.56% | 22.07% | 14.51% | 10.53% | 3.81% | 9.42% | 29.13% | 25.44% | 24.94% | 3.52% |
| EPS | 5.46 | 4.96 | 5.25 | 3.75 | 4.16 | 3.72 | 2.92 | 2.51 | 2.22 | 1.32 | 0.79 | 0.27 | 0.61 | 1.61 | 1.16 | 1.05 | 0.11 |
| EPS Diluted | 5.46 | 4.96 | 5.25 | 3.75 | 4.16 | 3.72 | 2.92 | 2.51 | 2.22 | 1.32 | 0.79 | 0.27 | 0.61 | 1.61 | 1.16 | 1.05 | 0.11 |
| Weighted Avg Shares Out | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M |
| Weighted Avg Shares Out (Dil) | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M | 23.85M |
Source: https://incomestatements.info
Category: Stock Reports